Treats Clostridium difficil e-associated diarrhea. ANDA 218130, held by Aurobindo Pharma. Vancomycin Hydrochloride.
As of Nov 16, 2026, ANDA 218130 (Vancomycin Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Aug 7, 2026, with 0 approved supplements and 0 published complete response letters.
Vancomycin hydrochloride for oral solution is indicated for the treatment of Clostridium difficil e-associated diarrhea in adults and pediatric patients less than 18 years of age. Vancomycin hydrochloride for oral solution is also indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in adults and pediatric patients less than 18 years of age. Important Limitations of Use Parenteral administration of vancomycin is not effective for the above infections; therefore, vancomycin must be given orally for these infections. Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 7, 2026 | Original application | Approved | None posted |
| Vancomycin HydrochlorideEQ 25MG BASE/ML · for solution;oral | Vancomycin Hydrochloride | Rx |
| Vancomycin HydrochlorideEQ 50MG BASE/ML · for solution;oral | Vancomycin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters